1. Introduction {#sec1-pharmaceutics-11-00432}
===============

Hydrogels are three-dimensional (3D) polymeric networks, whose hydrophilic structure allows the absorption of large amounts of water (thousands of times their dry weight) \[[@B1-pharmaceutics-11-00432]\]. Hydrogels consisting of synthetic polymers are currently gaining more interest than natural-derived polymers due to their enhanced life-time, higher capacity to absorb water \[[@B2-pharmaceutics-11-00432]\], improved mechanical properties \[[@B3-pharmaceutics-11-00432]\] and finely-tuned degradation \[[@B4-pharmaceutics-11-00432]\]. Depending on their structure, hydrogels can be chemically stable or easily degradable \[[@B5-pharmaceutics-11-00432]\]. According to the type of cross-linking between the polymers, hydrogels can be classified in physical, held together by non-covalent, reversible interactions and chemical hydrogels, linked by non-reversible covalent bonds \[[@B4-pharmaceutics-11-00432]\].

Their unique properties, including reliable biocompatibility, tunable mechanical and degradation features, sensitivity to various stimuli and the ability to be easily conjugated with hydrophilic and hydrophobic therapeutic compounds \[[@B4-pharmaceutics-11-00432]\] has made them important candidates in biomedical applications including drug delivery \[[@B6-pharmaceutics-11-00432]\], tissue engineering \[[@B7-pharmaceutics-11-00432],[@B8-pharmaceutics-11-00432],[@B9-pharmaceutics-11-00432]\], 3D cell cultures \[[@B10-pharmaceutics-11-00432]\], in vitro diagnostics and stem cell research \[[@B1-pharmaceutics-11-00432]\] ([Figure 1](#pharmaceutics-11-00432-f001){ref-type="fig"}).

In the therapeutic area, drug delivery approaches require outstanding improvements in obtaining safe transport systems in order to achieve the desired therapeutic effect and to avoid the side effects. Biomimetic strategies involving polymers describe innovative industrial products orientated to target therapy and controlled release. Hydrogels inspired design offer favorable conditions for therapeutic compounds encapsulation and protection. Furthermore, they are becoming biological responsive structures which ensure adequate biocompatibility and biodegradability.

2. Hydrogel Synthesis Methods {#sec2-pharmaceutics-11-00432}
=============================

Hydrogel synthesis is an essential step in developing new structures with beneficial properties for drug delivery action. The hydrogel structure is defined by the hydration of hydrophilic groups and domains of the polymers involved. Therefore, these groups and their interconnected chains create three-dimensional networks via crosslinking, avoiding their dissolution in the aqueous phase \[[@B2-pharmaceutics-11-00432],[@B11-pharmaceutics-11-00432]\].

The standard synthesis procedures imply polymerization and crosslinking. These techniques can happen in parallel in one step, or one after the other in multiple steps \[[@B2-pharmaceutics-11-00432]\].

Polymerization process is part of the gelation process. The structure and the conformation of the starting material influence the formation of soluble branched polymer networks \[[@B12-pharmaceutics-11-00432]\]. The starting material refers to polymer monomers, prepolymers, or hydrophilic polymers \[[@B13-pharmaceutics-11-00432]\]. The monomers and polyfunctional comonomers act as crosslinkers in network development. Sometimes polymerization is generated by radical initiators \[[@B14-pharmaceutics-11-00432],[@B15-pharmaceutics-11-00432]\] or photoinitiators \[[@B16-pharmaceutics-11-00432],[@B17-pharmaceutics-11-00432]\] like irradiation \[[@B18-pharmaceutics-11-00432],[@B19-pharmaceutics-11-00432],[@B20-pharmaceutics-11-00432]\].

Hydrophilic polymers are often used for hydrogel synthesis due to their biocompatibility \[[@B21-pharmaceutics-11-00432],[@B22-pharmaceutics-11-00432]\] in aqueous environments \[[@B23-pharmaceutics-11-00432]\] and mostly due to their loading drug potential \[[@B24-pharmaceutics-11-00432]\].

The swelling property of a hydrogel is significant for further use in medical applications because most of the body tissues are composed of large amounts of water \[[@B25-pharmaceutics-11-00432]\]. Swelling features of various polymers are advantageous for functionalization with therapeutic agents. On the other side, the effectiveness of such systems could consist of their capacity to deliver these agents without side outcomes.

The crosslinker agent plays a significant role in hydrogel swelling \[[@B26-pharmaceutics-11-00432]\] and degradation \[[@B27-pharmaceutics-11-00432]\]. It influences the physical properties of the final hydrogel product \[[@B28-pharmaceutics-11-00432]\]. Crosslinking methods imply covalent or non-covalent interactions between polymer monomers providing elastic characteristics \[[@B2-pharmaceutics-11-00432],[@B11-pharmaceutics-11-00432],[@B29-pharmaceutics-11-00432],[@B30-pharmaceutics-11-00432]\]. For this reason, two different types of hydrogels were identified: chemical gels based on covalent interactions ([Figure 2](#pharmaceutics-11-00432-f002){ref-type="fig"}C) and physical gels based on non-covalent interactions \[[@B11-pharmaceutics-11-00432]\] ([Figure 2](#pharmaceutics-11-00432-f002){ref-type="fig"}B).

On the other hand, there are factors involved in altering hydrogels assembly \[[@B31-pharmaceutics-11-00432]\]. Chemical stimuli (pH \[[@B32-pharmaceutics-11-00432],[@B33-pharmaceutics-11-00432]\], ionic strength \[[@B34-pharmaceutics-11-00432],[@B35-pharmaceutics-11-00432]\], solvent composition \[[@B36-pharmaceutics-11-00432]\], and molecules \[[@B37-pharmaceutics-11-00432]\]) ([Figure 2](#pharmaceutics-11-00432-f002){ref-type="fig"}A) lead to permanent gels. Physical stimuli (temperature \[[@B38-pharmaceutics-11-00432]\], electric field \[[@B39-pharmaceutics-11-00432]\], magnetic field \[[@B40-pharmaceutics-11-00432]\], light \[[@B16-pharmaceutics-11-00432],[@B41-pharmaceutics-11-00432]\], pressure \[[@B42-pharmaceutics-11-00432]\]) ([Figure 2](#pharmaceutics-11-00432-f002){ref-type="fig"}A) determine the reversible conversion between un-swollen and swollen state called phase transition. Biological stimuli (enzymes \[[@B43-pharmaceutics-11-00432]\], antigens \[[@B44-pharmaceutics-11-00432]\], and nucleic acids \[[@B45-pharmaceutics-11-00432]\]) ([Figure 2](#pharmaceutics-11-00432-f002){ref-type="fig"}A) affect the physical properties of the hydrogels like solubility \[[@B46-pharmaceutics-11-00432]\]. These stimuli-responsive polymers belong to the group of intelligent or smart materials \[[@B47-pharmaceutics-11-00432],[@B48-pharmaceutics-11-00432]\].

Smart polymers can form self-assembly structures through two significant procedures: using peptide/protein materials or using hybrid systems containing minimum a synthetic macromolecule and a peptide/protein motif \[[@B49-pharmaceutics-11-00432]\]. Their synthesis includes supramolecular chemistry and the control of the dynamic of supramolecular interactions and bonds for future media conditions \[[@B50-pharmaceutics-11-00432]\]. Proteins and peptides extend the system properties to degradability, stimuli-responsive phase transition, and also biological molecules targeting \[[@B51-pharmaceutics-11-00432]\]. Such smart hydrogels own convenient characteristics for drug delivery systems through their structural, morphological, and functional modifications occurred due to stimuli detection \[[@B52-pharmaceutics-11-00432]\]. These modifications ensure a time-dependent controlled release of the therapeutic agent with long circulation time converging to minimal side effects \[[@B53-pharmaceutics-11-00432]\].

3. Classification {#sec3-pharmaceutics-11-00432}
=================

Hydrogels can be classified considering different parameters like: polymer origin, ionic charge and biodegradability \[[@B54-pharmaceutics-11-00432]\].

According to the polymer origin, the hydrogel composition can be synthetic, natural or it can contain both synthetic and natural polymers and is called hybrid \[[@B55-pharmaceutics-11-00432]\]. Lately, the synthetic hydrogels are preferred due to their high water absorption properties, long life, and also a variety of chemistry which confers better strengthens and resistance in different conditions \[[@B2-pharmaceutics-11-00432]\].

Ionic charge influences the uptake of the charged drug molecules. A positively charged hydrogel will embed and release negatively charged low molecular weight molecules \[[@B56-pharmaceutics-11-00432]\]. Furthermore, the ionic charged hydrogels have implications on cellular interactions and behavior \[[@B57-pharmaceutics-11-00432]\].

Biodegradable hydrogels need to meet some specific features as biocompatibility and adaptability to various media conditions and preparation procedures. Such hydrogels are potential candidates for drug delivery applications because of their flexibility. Biodegradation process describes a chemical decomposition of a complex hydrogel into a simple structure through solubilizing or hydrolysis dictated by various external stimuli like pH, ionic strength, temperature or enzymes \[[@B27-pharmaceutics-11-00432]\]. Therefore, these hydrogels can be divided into chemical, physical and biological stimuli responsive categories.

Otherwise, non-biodegradable hydrogels offer multiple possibilities for tissue engineering applications by encapsulating growth factors, proteins \[[@B58-pharmaceutics-11-00432]\]. Other medical fields that are exploiting these type of hydrogels are plastic and reconstruction surgery, orthopedic implants, ocular lens, and microfluidic devices \[[@B59-pharmaceutics-11-00432]\].

[Table 1](#pharmaceutics-11-00432-t001){ref-type="table"} summarizes important classes of hydrogels and their properties and applications.

4. Hydrogel Functionalization with Therapeutic Agents {#sec4-pharmaceutics-11-00432}
=====================================================

Crosslinking synthesis methods make possible the functionalization with drugs and other therapeutic agents in order to develop new delivery systems \[[@B121-pharmaceutics-11-00432]\]. The hydrogel design describes cross-linked polymers and meshes that allow compound solution loading and diffusion. When functionalizing, the size of the meshes is to be taken into consideration \[[@B122-pharmaceutics-11-00432]\]. This procedure can be performed at two different times of hydrogel synthesis: at the beginning by mixing the drug with the other reagents or at the end after hydrogel is done \[[@B29-pharmaceutics-11-00432]\]. In situ loading method suits for hydrophilic drugs and is based on dissolving the drug into the water together with the polymer powder. The other technique is called post-loading and refers to dry hydrogel films immersion into drug solution for a certain period of time. In both of these cases, after drug incorporation, the hydrogel has a dried state and confers protection. In addition, cross-linkers are essential factors in controlled release of high or low molecular weight therapeutic agents, and in most cases the degradable cross-linkers are preferred \[[@B56-pharmaceutics-11-00432]\].

Wong and Dodou, 2017, synthesized poly(ethylene oxide) hydrogels cross-linked with pentaerythritol tetra-acrylate using ultraviolet light for cross-linking reaction. These hydrogel films were loaded with various drugs (lidocaine hydrochloride, diclofenac sodium and ibuprofen) using post-loading and in situ loading methods. The study results revealed that in situ loading procedure was more successful regarding drug encapsulation \[[@B123-pharmaceutics-11-00432]\].

Prince et al., 2019, used in situ loading technique for thermoresponsive poly(ϵ-caprolactone-co-lactide)-block-poly(ethylene glycol)-block-poly(ϵ-caprolactone-*co*-lactide) hydrogels functionalization with celecoxib. PEG's length affects hydrogel loading capacity and 2000 g/mol was found to be the optimal length for drug delivery applications \[[@B124-pharmaceutics-11-00432]\].

Many drugs and small molecules, especially the hydrophobic ones, can be encapsulated in order to enter the gel for further medical applications. For instance, many nanosystems (metallic \[[@B125-pharmaceutics-11-00432]\], lipid \[[@B126-pharmaceutics-11-00432]\], polymeric \[[@B127-pharmaceutics-11-00432]\], peptides \[[@B128-pharmaceutics-11-00432]\]) are used for targeted delivery \[[@B129-pharmaceutics-11-00432]\]. Nanoparticles are fashioned to ensure drug pharmacokinetics and pharmacodynamics \[[@B130-pharmaceutics-11-00432]\].

The use of nanoparticles can help the crosslinking reaction by adsorbing or attaching to polymer chains \[[@B131-pharmaceutics-11-00432]\], but also they can modify the hydrogel assembly properties \[[@B132-pharmaceutics-11-00432]\]. Due to the porous hydrogel structure, nanoparticles are easily embedded within a polymeric 3D network. This aspect is mandatory for achieving controlled release profile and can impede in choosing the right nanoparticles for drug molecules delivery, respectively those for hydrogel functionalization \[[@B133-pharmaceutics-11-00432]\]. Other nanoparticle physico-chemical properties like size, polydispersity index, and spatial orientation inside the gel need to be carefully adjusted \[[@B134-pharmaceutics-11-00432]\].

High loading capacity combined with controlled drug release and prolonged stability, will represent advantages for the newly designed system \[[@B135-pharmaceutics-11-00432]\].

Nanoparticle functionalized gels can perform targeted drug delivery in different ways: passive \[[@B136-pharmaceutics-11-00432]\], stimuli-responsive \[[@B137-pharmaceutics-11-00432]\], site-specific \[[@B138-pharmaceutics-11-00432]\] or detoxification manner \[[@B139-pharmaceutics-11-00432]\].

5. Characterization Methods {#sec5-pharmaceutics-11-00432}
===========================

When considering hydrogel characteristics usually investigated, the typical protocol will most probably compose of two kinds of tests: structural and functional. For structural analysis, an assortment of microscopy techniques have become, to a degree, the golden standard. As hydrogels are three dimensional, commonly optically clear, materials, conventional bright field microscopy is sparsely used. By far, the most common technique is Scanning Electron Microscopy (SEM). An extensive review of morphological characterization of hydrogels has been recently published \[[@B140-pharmaceutics-11-00432]\], and it implies that an SEM is a go-to instrument for hydrogel characterization regardless of composition. SEM imaging does require specialized sample preparation instrumentation, but the methodology was standardized to most gel types. Briefly, formalin fixed samples are dehydrated and freeze-dried, followed by either Au or Au/Pd sputtering under vacuum before imaging \[[@B141-pharmaceutics-11-00432]\]. Newer protocols forgo the fixation and dehydration steps \[[@B142-pharmaceutics-11-00432]\] even though there is evidence that liquid nitrogen snap freezing followed by freeze-drying induces gel shrinkage and incorrect evaluation of pore size \[[@B143-pharmaceutics-11-00432],[@B144-pharmaceutics-11-00432]\]. SEM is generally used to asses pore formation and pore size \[[@B145-pharmaceutics-11-00432]\], crosslinking status \[[@B146-pharmaceutics-11-00432]\] and the effect certain loading compounds have on general gel structure \[[@B147-pharmaceutics-11-00432]\].

While SEM does provide valuable qualitative information, alternatives do exist and can potentially provide complementary information to the limited capacity of regular SEM of generating two-dimensional projections. Laser scanning confocal microscopy (LSCM), used in combination with fluorescent dyes is capable of generating Z-stacks to evaluate similar aspects (i.e., pore dimensions and shape) to SEM \[[@B140-pharmaceutics-11-00432],[@B148-pharmaceutics-11-00432]\]. Where LSCM shines is the complementary characterization capacity it has. Hydrogel loading and unloading of solutes \[[@B149-pharmaceutics-11-00432]\], dispersion and mobility of the solute \[[@B150-pharmaceutics-11-00432]\] or distribution of solid loading materials \[[@B151-pharmaceutics-11-00432]\] are tested with the condition that the solute (or other compounds of interest) is fluorescent or can be spiked/bound to a fluorescent marker. Structural characteristics, along with mechanical proprieties, can also be observed by different variations of Scanning Probe Microscopy. It was proved that the elastic modulus of the gel correlates is correlated with cell differentiation \[[@B152-pharmaceutics-11-00432]\] and migration \[[@B153-pharmaceutics-11-00432]\]. As the modulus of the hydrogel correlates with the degree of polymer cross-linkage \[[@B154-pharmaceutics-11-00432]\] and cross-linkage to solute mobility through the gel \[[@B155-pharmaceutics-11-00432]\], Atomic Force Microscopy is a powerful multimodal analysis tool in the characterization of hydrogels, allowing not only topological and roughness investigations but also functional ones. Of course, all the techniques presented can be used in parallel or correlatively to offer complementary information or potentially highly specific characteristics such as individual pore mechanics \[[@B156-pharmaceutics-11-00432]\].

Functional analysis is paramount to understanding the effects that solute/external stimuli have on the hydrogel. The most important ones seem to be: absorption capacity and rate, absorbency under load, lowest solute, and extra monomer level, pH, and photostability \[[@B2-pharmaceutics-11-00432]\]. Drug release from the hydrogel is usually a function of the diffusion capacity of the drug and the retention capacity of the gel. This is most commonly measured by dynamically probing the concentration of the drug in the medium of interest and plotting the concentration against a certain time interval or as a percentage. The actual analysis is highly dependent of the nature of the tested compound and can range from HPLC for peptides \[[@B157-pharmaceutics-11-00432]\], electrochemical probing for gases such as H~2~S \[[@B158-pharmaceutics-11-00432]\] or various fluorescence/colorimetric/absorbancy tests.

The controlled release can be achieved through various strategies based on hydrogel composition and properties. For instance, there are some molecules that can initiate and enhance the degradation rate \[[@B159-pharmaceutics-11-00432],[@B160-pharmaceutics-11-00432]\]. Matrix-metalloproteinases family members can cleave the oligo-peptide bonds \[[@B161-pharmaceutics-11-00432]\]. Other examples are represented by glucose \[[@B162-pharmaceutics-11-00432]\] and thrombin \[[@B163-pharmaceutics-11-00432]\], which are playing important roles in physiological processes. On the other hand, external stimuli \[[@B164-pharmaceutics-11-00432],[@B165-pharmaceutics-11-00432]\] can determine hydrogel networks disruption. Hydrogels swelling capacity is an important target for the sustained release mechanism \[[@B166-pharmaceutics-11-00432]\] and is also influenced by stimuli sensitivity \[[@B167-pharmaceutics-11-00432]\].

In addition, hydrogel mechanical deformation using magnetic field or ultrasounds is a very common procedure. In this regard, Liu et al., 2006, proposed an intelligent magnetic hydrogel loaded with drug molecules capable of tunable controlled release profile time dependent \[[@B168-pharmaceutics-11-00432]\]. Ultrasound guided drug release approach was digitally integrated into ionically crosslinked hydrogels \[[@B169-pharmaceutics-11-00432]\].

Many mathematical models are used for predicting the drug delivery efficiency of polymeric hydrogels. These determinations are based on mesh size, mechanical, mass-transport and diffusion behavior using hydrodynamics, obstruction, free volume and combined theories \[[@B166-pharmaceutics-11-00432],[@B170-pharmaceutics-11-00432]\].

6. In Vivo Biocompatibility and Biodegradability {#sec6-pharmaceutics-11-00432}
================================================

In order to compare and investigate the effects of hydrogels in vivo, it is necessary to evaluate its biocompatibility, since living organisms are prone to develop inflammatory reactions which are facilitated by the degradation of the synthetic polymers \[[@B171-pharmaceutics-11-00432]\]. As stated in a review by Naahidi et al., hydrogel toxicity and biocompatibility is dependent on the breakdown of the polymer into monomers or oligomers, the crosslinking agents or trace polymerization agents \[[@B172-pharmaceutics-11-00432]\]. Besides achieving favorable hydrogel formulations for drug delivery, the main challenges are performing toxicity screening \[[@B173-pharmaceutics-11-00432]\], maintaining long-term stability, and controlling the release properties of the therapeutic agents. One favorable aspect of hydrogel research has been its longevity. The over 100 years of research have produced gel-like biopolymers with low toxicity and high biocompatibility, especially those derived from natural molecules such as collagen, chitosan, fibrin, and hyaluronic acid \[[@B174-pharmaceutics-11-00432]\]. However, while previous in vitro studies have shown promising results regarding the biodegradability and biocompatibility of these compounds, further in vivo studies are necessary at this point \[[@B175-pharmaceutics-11-00432]\].

7. Hydrogel Administration {#sec7-pharmaceutics-11-00432}
==========================

As mentioned above, a complex problem regarding the administration of various biomaterials in vivo reflects the ability of the material to conserve and promote a biologically safe environment for the subjected animals. In vivo testing is challenging because there still is a need for an established and reliable animal model in order to achieve biomechanical restoration. Following these standards, different injectable hydrogels protocols were developed and optimized, which because the body very well tolerated them, are ideal candidates for performing in vivo testing on rodents \[[@B176-pharmaceutics-11-00432]\]. Given the fact that these delivery systems are suitable for clinical use, the most accessible routes of administration are subcutaneous \[[@B177-pharmaceutics-11-00432]\], oral \[[@B178-pharmaceutics-11-00432]\], rectal \[[@B179-pharmaceutics-11-00432]\], topical and transdermal \[[@B180-pharmaceutics-11-00432]\], orthotopic \[[@B181-pharmaceutics-11-00432]\], intraperitoneal \[[@B182-pharmaceutics-11-00432]\] and ocular \[[@B183-pharmaceutics-11-00432]\]. [Figure 3](#pharmaceutics-11-00432-f003){ref-type="fig"} represents all these administration routes.

7.1. Subcutaneous Hydrogel Delivery System {#sec7dot1-pharmaceutics-11-00432}
------------------------------------------

One of the most efficient methods to evaluate the response to the therapy and assessing the toxic response in vivo in mice is performing a subcutaneous injection. Since the subcutaneous area is vascularized, the implanted hydrogels or other biomaterials are immune privileged, so a mild reaction to foreign moieties is to be expected \[[@B176-pharmaceutics-11-00432]\]. Bare polyethylene hydrogels have been proven to not exhibit cytotoxicity in murine models even after 60 days when injected subcutaneously \[[@B184-pharmaceutics-11-00432]\]. Similar results regarding biocompatibility were obtained with ellagic acid hydrogels \[[@B185-pharmaceutics-11-00432]\], nano-patterned poly-acrylamide hydrogels \[[@B186-pharmaceutics-11-00432]\] chitosan and gelatin hydrogels \[[@B187-pharmaceutics-11-00432],[@B188-pharmaceutics-11-00432]\], alginate \[[@B189-pharmaceutics-11-00432]\] and pectin \[[@B190-pharmaceutics-11-00432]\]. It is worth mentioning that the majority of the studies do report mild inflammatory responses.

7.2. Oral Delivery {#sec7dot2-pharmaceutics-11-00432}
------------------

The oral delivery route represents by far the most convenient solution under adjustable parameters and patient compliance \[[@B191-pharmaceutics-11-00432]\]. Orally administered hydrogels should provide bioavailability depending on medium particularities, such as pH variations along the intestinal tract \[[@B192-pharmaceutics-11-00432]\]. MPEG, caprolactone and, itaconic acid pH-sensitive hydrogels were tested for acute oral toxicity in BALB/c mice and showed no signs of toxicity \[[@B193-pharmaceutics-11-00432]\]. When considering oral ingestion, the metabolic effect that monomers have on the organism is very significant. Poly-glycolic and poly-lactic-*co*-glycolic acid hydrogel degradation have been shown to affect healthy metabolism \[[@B172-pharmaceutics-11-00432]\], leading to some limitations in terms of hydrogel therapy such as:Presence of digestive enzymes could lead to denaturation;Low permeability through the epithelial membrane into the bloodstream;Superior and inferior digestive systems can represent potential therapeutic targets \[[@B194-pharmaceutics-11-00432]\].

7.3. Rectal Delivery {#sec7dot3-pharmaceutics-11-00432}
--------------------

Rectal administration offers plenty of advantages such as rapid absorption of the compound, avoidance of the gastrointestinal tract, limited adverse reactions of the therapeutics, and provides controlled release of the compound in the context of the stable environmental conditions encountered in the rectum. Based on an earlier study that showed excellent biocompatibility on the digestive tract \[[@B195-pharmaceutics-11-00432]\], rectally administrated catechol-chitosan- based hydrogels with mucoadhesive properties have been tested in murine models and show no toxic effects after 10 days \[[@B196-pharmaceutics-11-00432]\]. Regarding this issue, Afaf A. et al., developed a hydrogel-based product and made a correlation between in vitro and in vivo profile with promising results \[[@B179-pharmaceutics-11-00432]\].

7.4. Topical and Transdermal Delivery {#sec7dot4-pharmaceutics-11-00432}
-------------------------------------

Hydrogel therapy is suitable for the topical and transdermal approach. Nowadays, the general concept about nanosystems in the context of skin penetration is that the skin barrier restricts the delivery via epidermis and dermis. In truth, hydrogel penetration through the skin seems unlikely as the macroscale mesh-like structure would prohibit penetration and has been shown, in the case of collagen hydrogels, to not even affect burn models \[[@B197-pharmaceutics-11-00432]\]. Various alternative hydrogel formulations are commonly tested on graft donors with no discernable side effects compared to other gel-based formulations commonly used in hospital environments \[[@B198-pharmaceutics-11-00432]\]. Recent studies demonstrated that this method of delivery is reliable as a delivery system for nanoparticles with various roles, and it only depends on nanoparticles diameter, charge, and structure. The coating influences the penetration rate. Peptide layered nanocarriers are more efficient than pegylated ones. Ex vivo studies were carried out, using skin samples collected from mouse and human through surgical resection \[[@B199-pharmaceutics-11-00432]\].

7.5. Orthotopic Injections {#sec7dot5-pharmaceutics-11-00432}
--------------------------

Administration of hydrogels via intratumoral injection is a practical approach, which requires the release of the nanostructure system loaded in a hydrogel matrix. These hydrogel structures are so-called "macroscopic gels" that are coming with the imperative need to decrease potential damages of associated tissues during an injection \[[@B200-pharmaceutics-11-00432]\]. Qinjie Wu et al., 2015 synthesized a smart hydrogel responsive to temperature, which prevented the formation of peritoneal adhesion on a damaged abdominal wall \[[@B181-pharmaceutics-11-00432]\]. Where orthotopic treatment using hydrogels seems to show promise is in the post-resection cavity where it can act as a slow release to improve long term survival \[[@B201-pharmaceutics-11-00432],[@B202-pharmaceutics-11-00432]\].

7.6. Intraperitoneal Delivery {#sec7dot6-pharmaceutics-11-00432}
-----------------------------

Intraperitoneal administration of hydrogel systems shows promising results and is considered to be a noninvasive option, as well as an optimal formulation for various pharmaceutical agents. One of these structures was prepared by Chih-Hao Chen et al., in 2018 and was successfully incorporated in the mouse peritoneum achieving dual action: drug delivery and postoperative anti-adhesiveness \[[@B203-pharmaceutics-11-00432]\]. Similarly to orthotopic injected hydrogels, intraperitoneal hydrogels (mostly gelatin based gels) by themselves show no cytotoxicity and high degrees of biocompatibility \[[@B204-pharmaceutics-11-00432]\]. It is worth mentioning that the capacity of the gels to absorb high amounts of water could be detrimental in the case of any injectable formulations \[[@B182-pharmaceutics-11-00432]\].

7.7. Ocular Delivery {#sec7dot7-pharmaceutics-11-00432}
--------------------

Formulations for ocular delivery are complicated to develop; several implications are creating limitations like inferior bioavailability and absorption \[[@B183-pharmaceutics-11-00432]\]. Eye topical applications can be performed but with minimal disease addressability. Delivering therapeutic agents in maximum concentrations needed in the posterior segment encounters failure in most of the cases \[[@B205-pharmaceutics-11-00432]\]. However, for a better approach of the posterior segment, intraocular injections are more operative, but in this case, ocular complications are the primary concern. There are still other approaches like intravitreal, intracameral or peri-ocular injections, but with a significant risk of side effects \[[@B206-pharmaceutics-11-00432]\]. Improvements in protocols alongside adaptations of in vivo performance for sustainable results are needed. The standard hydrogels used for contact lenses (silicone and polymethylemethacrylate) are, however, generally highly biocompatible with almost 50 years of results proving it \[[@B207-pharmaceutics-11-00432]\]. Some issues with silicone hydrogels causing eye inflammation have been reported \[[@B208-pharmaceutics-11-00432]\] but, the only specific limitation to capable hydrogel based therapeutics seem to be those mentioned above.

7.8. Tissue Engineering and Bone Repair {#sec7dot8-pharmaceutics-11-00432}
---------------------------------------

Innovative biocompatible and biodegradable injectable hydrogels have been synthesized for cartilage and bone tissue \[[@B209-pharmaceutics-11-00432]\], vascular tissue, skin, and other soft tissues engineering \[[@B210-pharmaceutics-11-00432]\]. In this regard, the viscosity of the hydrogel plays a significant role together with sol-gel transition in specific physiological environment \[[@B210-pharmaceutics-11-00432]\].

The injectable systems have the flexibility to fill irregular-shaped defects and offer the possibility to reduce surgical invasion \[[@B211-pharmaceutics-11-00432]\]. Significant current research strategies have been reported regarding the use of autografts in bone implantation therapy, due to the advantage of minimized rejection rates \[[@B212-pharmaceutics-11-00432]\]. Recent attempts have been made in injectable bio hydrogels (collagen \[[@B213-pharmaceutics-11-00432]\], chitosan \[[@B214-pharmaceutics-11-00432]\], gelatin \[[@B215-pharmaceutics-11-00432]\], cellulose \[[@B97-pharmaceutics-11-00432]\]) in cell-based therapies to increase biomimetic capacity. For instance, Park and Lee developed an oxidized alginate/hyaluronic acid hydrogel construct and tested it together with chondrocytes in vivo on mice, and obtained positive results on cartilage regeneration \[[@B216-pharmaceutics-11-00432]\].

Among these, stem cell delivery systems are focusing on microfluidics to avoid microenvironment interactions. Various hydrogel constructs like microspheres were fromulated for stem cells encapsulation. For example, Zhao et al., 2016, synthesized light responsive hydrogel microspheres made by gelatin and methacryloyl chloride. Bone marrow-derived mesenchymal stem cells were encapsulated using post-loading procedures and then tested in vivo on rabbit femoral condyle animal model following orthotopic implantation protocol. This microfluidic approach demonstrates the feasibility of this method in osteogenesis \[[@B217-pharmaceutics-11-00432]\].

In situ gel forming tissue implants are suitable for transplantation during invasive surgeries directly into defects. The difficult regeneration of articular cartilage represents a very challenging problem. Due to the fact that this tissue is not presenting vascularization, the immune response is absent and it allows the use of allogenic constructs in the context of tissue engineering matter. Perrier-Groult et al., 2019, implemented a protocol for subcutaneous administration of agarose hydrogels embedded with human chondrocytes in order to promote their differentiation to cartilage matrix. In this regard, humanized mouse models are preferred for the evaluation of such implants acceptance \[[@B218-pharmaceutics-11-00432]\].

Considering the aspects mentioned above, when choosing the experimental design for in vivo studies using murine models, the age of the animal should be considered because it can influence the outcomes through various metabolic pathways involved in hydrogels degradation and clearance \[[@B175-pharmaceutics-11-00432]\].

Regarding hazard assessment, many different hydrogel systems aim to deliver the therapeutic agent in a controlled manner for better effects at the target site \[[@B219-pharmaceutics-11-00432]\]. In a general approach to a pathology, orthotopic murine models simulate clinical conditions with better accuracy than cell line-based models, due to proper exposure to a microenvironment that is more similar to the pathological status in human \[[@B220-pharmaceutics-11-00432]\]. Therefore, orthotropic animal models should be implemented in order to improve the response to therapy significantly.

8. Clinical Trials {#sec8-pharmaceutics-11-00432}
==================

Bringing together the advantages of a biocompatible hydrogel with the therapeutic effect of various molecules provides new efficient configurations adapted for medical devices development. Polymer science is holding up the attention of scientists because of the promising properties of biomedical clinical applications.

In the last decade, an increasing number of clinical trials investigated the use of hydrogel structures for drug delivery systems. According to [ClinicalTrials.gov](ClinicalTrials.gov), over 300 completed studies are presenting encouraging results for hydrogel use with significant applicability in visual disorders and dermatological affections. [Table 2](#pharmaceutics-11-00432-t002){ref-type="table"} emphasizes prominent examples of such products.

9. Future Perspectives {#sec9-pharmaceutics-11-00432}
======================

In the frame of current work, hydrogels aim to become feasible tools for microfluidics, biosensing and tissue regeneration engineering (potential scaffold for new tissues and organs). Future proposed designs highlight the control over structural and morphological properties in order to improve their biomimetic capabilities.

Furthermore, hydrogel usage in generating complex 3D multi-cell models offers promise in reducing the number of animals used for testing and while at the same time provides medium that more closely resembles aspects of the human body. All of these considerations will inevitably lead to accelerating pharmaceutical formulation development and deployment on the market. It is truly difficult to exemplify the role and applications that hydrogels have in biomedical research mainly due to their usage not being restricted to the topics described in this review. It is, however, easy to observe the capacity that this technology has to transcend a certain niche and in a very timely manner be implemented in a completely new field of work. The most difficult hurdles for medical and biological research seem to have been overcome and hydrogels have become a common day item in not only researchers' lives but the general public's lives too.

Recently, electronics progress relieves the use of hydrogel technology for healthcare oriented applications. Lab-on-a-chip microfluidic devices are considered practical and compelling for diagnostic and drug screening investigations. The generation of wearable sensors represents an innovative platform able to monitor pathological particularities of the human subject. Such devices can also perform a controlled release of pharmaceutical formulations according to the monitored parameters.

What is clear is the fact that hydrogels have been and are continuing to be relevant "scaffolds" in biomedicine and biomedical research. When it comes to these constructs we have entered an era of fine-tuning already existing structures and technology, where novel hydrogels are quick to reach practical applications in the real world (contact lenses, wound dressing, 3D culture scaffolds) and more exotic ones hold potential in a variety of fields such as robotics, aerospace engineering, solar cells and photoreactors, environmental research and sports science.
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![Hydrogel medical applications.](pharmaceutics-11-00432-g001){#pharmaceutics-11-00432-f001}

![Stimuli sensitive hydrogels structural changes. (**A**) Stimuli categories: physical, biological and chemical. (**B**) Physical hydrogels are non-covalently crosslinked and in an aqueous environment, they swell. Under various stimuli presence, they undergo reversible structure modifications and release the compound. (**C**) Chemical hydrogels describes covalently crosslinked formulation that swells in aqueous conditions and then suffers reversible or irreversible alterations depending on stimuli presence and crosslinking strength, which influence their discharge.](pharmaceutics-11-00432-g002){#pharmaceutics-11-00432-f002}

![In vivo drug delivery hydrogel routes of administration. There are various methods for in vivo administration of hydrogel based products depending on the pathological conditions and their localization. Subcutaneous injection plays a crucial role in toxicological effects evaluation. Topical or transdermal application is preferred for skin associated problems. Orthotopic and intraperitoneal injections are non-invasive techniques which ensure good therapy results. On the other hand, oral administration has some limitations because of digestive enzymes.](pharmaceutics-11-00432-g003){#pharmaceutics-11-00432-f003}
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###### 

Hydrogel classification according various parameters, their properties and corresponding applications.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                        Hydrogel Type                                                                                                                                          Hydrogel Composition                                                                                                                                                       Properties                                                                                                                                                                   Applications
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemical stimuli                 pH responsive                                                                                                                                          Carboxylated agarose/tannic acid hydrogel scaffolds cross-linked with zinc ions \[[@B60-pharmaceutics-11-00432]\]\                                                         Sustained release of the incorporated drugs \[[@B60-pharmaceutics-11-00432]\]\                                                                                               Drug delivery \[[@B54-pharmaceutics-11-00432],[@B60-pharmaceutics-11-00432]\]\
                                                                                                                                                                                          Poly(acrylamide-*co*-acrylic acid) poly(AAm-*co*-AAc) hydrogels \[[@B61-pharmaceutics-11-00432]\]                                                                          Biocompatibility \[[@B60-pharmaceutics-11-00432]\]\                                                                                                                          Sensing \[[@B63-pharmaceutics-11-00432]\]
                                                                                                                                                                                                                                                                                                                                                                     Strong electrostatic interactions and stability \[[@B61-pharmaceutics-11-00432]\]\                                                                                           
                                                                                                                                                                                                                                                                                                                                                                     Increased hydrophilicity and swelling \[[@B62-pharmaceutics-11-00432]\]                                                                                                      

  Ionic strength responsive        2-acrylamido-2-methylpropane sulfonic acid crosslinked with *N*,*N*'-methylene(bis)acrylamide \[[@B34-pharmaceutics-11-00432]\]\                       Increased swelling properties \[[@B34-pharmaceutics-11-00432]\]\                                                                                                           Depollution of aqueous ecosystems \[[@B64-pharmaceutics-11-00432]\]\                                                                                                         
                                   Poly(*N*-isopropylacrylamide) crosslinked with imidazolium-based dicationic ionic liquid \[[@B64-pharmaceutics-11-00432]\]                             Controllable porous structure \[[@B34-pharmaceutics-11-00432]\]\                                                                                                           Drug and gene delivery \[[@B47-pharmaceutics-11-00432]\]\                                                                                                                    
                                                                                                                                                                                          Biodegradability \[[@B65-pharmaceutics-11-00432]\]                                                                                                                         Tissue engineering \[[@B47-pharmaceutics-11-00432]\]                                                                                                                         

  Solvent composition responsive   Fluorenylmethoxycarbonyl diphenylalanine \[[@B36-pharmaceutics-11-00432]\]\                                                                            Uniform networks \[[@B36-pharmaceutics-11-00432]\]\                                                                                                                        Sensing \[[@B68-pharmaceutics-11-00432]\]                                                                                                                                    
                                   Poly(*N*-isopropylacrylamide) and poly(*N*,Ndimethylacrylamide) mixtures \[[@B66-pharmaceutics-11-00432]\]\                                            Swelling behaviour responsive to temperature too \[[@B66-pharmaceutics-11-00432]\]\                                                                                                                                                                                                                                                                     
                                   Poly(*N*-isopropylacrylamide) \[[@B67-pharmaceutics-11-00432],[@B68-pharmaceutics-11-00432]\]                                                          High porosity, Heterogeneous structure \[[@B67-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                                                

  Molecules responsive             *N*-isopropylacrylamide crosslinked with *N*,*N*′-methylenebis(acrylamide) \[[@B69-pharmaceutics-11-00432]\]\                                          Achieves molecular recognition, High affinity and specificity \[[@B71-pharmaceutics-11-00432]\]\                                                                           Sensing \[[@B73-pharmaceutics-11-00432]\]\                                                                                                                                   
                                   Acrylamide crosslinked with polyethylene glycol \[[@B70-pharmaceutics-11-00432]\]                                                                      Controlled assembly \[[@B72-pharmaceutics-11-00432]\]\                                                                                                                     Drug delivery \[[@B37-pharmaceutics-11-00432]\]\                                                                                                                             
                                                                                                                                                                                          Controlled release \[[@B43-pharmaceutics-11-00432]\]\                                                                                                                      Cell culture \[[@B72-pharmaceutics-11-00432]\]                                                                                                                               
                                                                                                                                                                                          Enzyme responsive \[[@B70-pharmaceutics-11-00432]\]\                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                          Antigen responsive \[[@B69-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                                                                    

  Physical stimuli                 Temperature responsive                                                                                                                                 *N*-trimethyl chitosan chloride polymers crosslinked with poly(ethylene glycol) and glycerophosphate \[[@B74-pharmaceutics-11-00432]\]\                                    Two categories: low critical solution temperature \[[@B74-pharmaceutics-11-00432]\] and upper critical solution temperature \[[@B75-pharmaceutics-11-00432]\]\               Tissue engineering \[[@B76-pharmaceutics-11-00432],[@B77-pharmaceutics-11-00432],[@B78-pharmaceutics-11-00432],[@B82-pharmaceutics-11-00432]\], Drug delivery \[[@B80-pharmaceutics-11-00432],[@B82-pharmaceutics-11-00432]\]
                                                                                                                                                                                          Poly(*N*-vinylcaprolactam) grafted with poly(ethylene oxide) \[[@B75-pharmaceutics-11-00432]\]\                                                                            Sol --gel transition at 37 °C \[[@B79-pharmaceutics-11-00432]\]\                                                                                                             
                                                                                                                                                                                          Poly(*N*-isopropylacrylamide) and aminated alginate \[[@B76-pharmaceutics-11-00432]\]\                                                                                     Easy functionalization with drug molecules \[[@B80-pharmaceutics-11-00432]\] Unique physical properties similar to extracellular matrix \[[@B81-pharmaceutics-11-00432]\]\   
                                                                                                                                                                                          Poly(*N*-vinylcaprolactam) \[[@B77-pharmaceutics-11-00432]\]\                                                                                                              Controlled degradation \[[@B76-pharmaceutics-11-00432]\]                                                                                                                     
                                                                                                                                                                                          Methoxy poly(ethylene glycol)-poly(pyrrolidone-*co*-lactide) \[[@B78-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                          

  Electric field responsive        Polypyrrole polymeric nanoparticles loaded in poly lactic-*co*-glycolic acid and poly(ethyleneglycol) hydrogel \[[@B83-pharmaceutics-11-00432]\]       Controlled release of the cargo \[[@B84-pharmaceutics-11-00432]\] depending on the strength or the duration of applied electric field \[[@B83-pharmaceutics-11-00432]\]\   Drug delivery \[[@B84-pharmaceutics-11-00432]\]                                                                                                                              
                                                                                                                                                                                          Biocompatibility, Minimal invasiveness \[[@B83-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                                                

  Magnetic field responsive        Hemicellulose crosslinked with O-acetyl-galactoglucomannan \[[@B85-pharmaceutics-11-00432]\]\                                                          Successful absorption and controlled release of drugs \[[@B85-pharmaceutics-11-00432]\]\                                                                                   Tissue engineering \[[@B86-pharmaceutics-11-00432]\]\                                                                                                                        
                                   Gelatin hydrogels loaded with magnetic nanoparticles \[[@B86-pharmaceutics-11-00432]\]                                                                 Some of them dispose of anisotropic properties \[[@B87-pharmaceutics-11-00432]\]                                                                                           Microfluidics, drug delivery, contrast agents \[[@B88-pharmaceutics-11-00432]\]                                                                                              

  Light responsive                 Hydroxypropyl methylcellulose and Carbopol hydrogels containing diclofenac-sodium chitosan microspheres \[[@B89-pharmaceutics-11-00432]\]\             Reasonable strengthens according to application \[[@B89-pharmaceutics-11-00432]\]\                                                                                         Drug delivery \[[@B89-pharmaceutics-11-00432]\]\                                                                                                                             
                                   Poly\[2-((4,5-dimethoxy-2-nitrobenzyl)oxy)-*N*-(2-(methacryloyloxy)ethyl)-*N*, *N*-dimethyl-2-oxoethan-1-aminium\] \[[@B90-pharmaceutics-11-00432]\]   Reversible and irreversible, Spatiotemporal control over functional groups, Controlled release \[[@B91-pharmaceutics-11-00432]\]                                           Self-sterilization and self-cleaning \[[@B90-pharmaceutics-11-00432]\]\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                     Microfluidics \[[@B92-pharmaceutics-11-00432]\]                                                                                                                              

  Pressure responsive              Polyacrylamide and poly(acrylamide-hydroxyethyl methacrylate) \[[@B93-pharmaceutics-11-00432]\]                                                        Thermo- and pH sensitive \[[@B94-pharmaceutics-11-00432]\]\                                                                                                                Sensing \[[@B95-pharmaceutics-11-00432]\]\                                                                                                                                   
                                                                                                                                                                                          Adhesion capacity, elasticity \[[@B93-pharmaceutics-11-00432]\]                                                                                                            Drug delivery \[[@B96-pharmaceutics-11-00432]\]                                                                                                                              

  Polymer origin                   Natural                                                                                                                                                Nanofibrillar cellulose \[[@B97-pharmaceutics-11-00432]\]\                                                                                                                 Biomimetic and adhesion capacity \[[@B101-pharmaceutics-11-00432]\]\                                                                                                         Tissue engineering \[[@B101-pharmaceutics-11-00432],[@B103-pharmaceutics-11-00432],[@B104-pharmaceutics-11-00432]\], Drug delivery, Sensing \[[@B102-pharmaceutics-11-00432]\]
                                                                                                                                                                                          Thiolated gelatin-poly(ethylene glycol) diacrylate \[[@B98-pharmaceutics-11-00432]\]\                                                                                      Mechanical support for cell development \[[@B102-pharmaceutics-11-00432]\]                                                                                                   
                                                                                                                                                                                          Methacrylated gelatin \[[@B99-pharmaceutics-11-00432]\]\                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                          Polycaprolactone sandwiched in a gelatin-chitosan hydrogel \[[@B100-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                           

  Synthetic                        Low acyl gellan gum bilayered hydrogel scaffolds \[[@B105-pharmaceutics-11-00432]\]\                                                                   Controllable structure and other physico-chemical properties \[[@B102-pharmaceutics-11-00432]\]\                                                                           Drug delivery \[[@B106-pharmaceutics-11-00432]\]\                                                                                                                            
                                   *N*-isopropylacrylamide and itaconic acid \[[@B106-pharmaceutics-11-00432]\]\                                                                          Stimuli responsive \[[@B106-pharmaceutics-11-00432]\]                                                                                                                      Tissue engineering \[[@B108-pharmaceutics-11-00432]\]                                                                                                                        
                                   Poly(ethylene glycol)---poly(propylene glycol) copolymers \[[@B107-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                                                                                                                                                                                   

  Hybrid                           Alginate-polymethacrylate \[[@B109-pharmaceutics-11-00432]\]\                                                                                          Biomimetic capacity \[[@B109-pharmaceutics-11-00432]\]\                                                                                                                    Tissue engineering, drug delivery \[[@B112-pharmaceutics-11-00432]\]\                                                                                                        
                                   Chondroitin sulfate and poly(ethylene glycol) \[[@B110-pharmaceutics-11-00432]\]\                                                                      Multicomponent \[[@B112-pharmaceutics-11-00432]\]\                                                                                                                         Wound-healing \[[@B111-pharmaceutics-11-00432]\]                                                                                                                             
                                   Chitosan/hyaluronic acid hydrogels loaded with poly (lactic-*co*-glycolic acid) microspheres \[[@B111-pharmaceutics-11-00432]\]                        Heterogeneous composition \[[@B113-pharmaceutics-11-00432]\]\                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                          Responsive to environment changes \[[@B114-pharmaceutics-11-00432]\]                                                                                                                                                                                                                                                                                    

  Biodegradability                 Biodegradable                                                                                                                                          Chitosan-gelatin \[[@B115-pharmaceutics-11-00432]\]\                                                                                                                       Stable and biocompatible \[[@B116-pharmaceutics-11-00432]\]\                                                                                                                 Drug delivery \[[@B116-pharmaceutics-11-00432]\]\
                                                                                                                                                                                          Pectin-*co*-poly(methacrylic acid) \[[@B116-pharmaceutics-11-00432]\]                                                                                                      Biomimetic capacity \[[@B117-pharmaceutics-11-00432]\]\                                                                                                                      Tissue engineering \[[@B117-pharmaceutics-11-00432]\]
                                                                                                                                                                                                                                                                                                                                                                     Natural and synthetic polymeric structure \[[@B117-pharmaceutics-11-00432]\]\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                     Stimuli responsive \[[@B118-pharmaceutics-11-00432]\]                                                                                                                        

  Non-biodegradable                Poly(2-hydroxyethyl methacrylate) \[[@B58-pharmaceutics-11-00432]\]\                                                                                   Biocompatibility \[[@B58-pharmaceutics-11-00432]\]\                                                                                                                        Tissue engineering \[[@B58-pharmaceutics-11-00432]\]\                                                                                                                        
                                   Poly(2-hydroxyethyl methacrylate)/trimethylolpropane trimethacrylate \[[@B119-pharmaceutics-11-00432]\]                                                Sustained release and recharge \[[@B119-pharmaceutics-11-00432]\]                                                                                                          Drug delivery \[[@B119-pharmaceutics-11-00432]\]\                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                     Plastic and reconstruction surgery \[[@B120-pharmaceutics-11-00432]\]                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

pharmaceutics-11-00432-t002_Table 2

###### 

Different completed clinical trials using hydrogel based products ([ClinicalTrials.gov](ClinicalTrials.gov)).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                         Product                                                                         Benefits                                                                                                    Reference
  ------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Prostate cancer radiotherapy                      Hydrogel spacer                                                                 Minimal side effects and toxicity\                                                                          \[[@B221-pharmaceutics-11-00432],[@B222-pharmaceutics-11-00432]\]
                                                                                                                                    Improves rectal dosimetry\                                                                                  
                                                                                                                                    Reduces the rates of rectal toxicity                                                                        

  Gynecologic laparoscopic surgery                  Crosslinked hyaluronan gel                                                      Safety use\                                                                                                 \[[@B223-pharmaceutics-11-00432]\]
                                                                                                                                    Minimizes postoperative adhesion formation throughout the abdominopelvic cavity                             

  Corneal epithelial permeability                   Silicone hydrogel contact lenses                                                Improves epithelial permeability when used with ophthalmic solutions                                        \[[@B224-pharmaceutics-11-00432]\]

  Corneal infiltrates                               Identification of bacterial species during continuous wear of contact lenses\   \[[@B225-pharmaceutics-11-00432],[@B226-pharmaceutics-11-00432]\]                                           
                                                    Improved cornea response to contact lenses                                                                                                                                                  

  Myopia                                            Good ocular comfort\                                                            \[[@B227-pharmaceutics-11-00432]\]                                                                          
                                                    High oxygen transmissibility                                                                                                                                                                

  Dry eye syndrome                                  Crosslinked hyaluronic acid with liposomes and crocin                           Safety profile\                                                                                             \[[@B228-pharmaceutics-11-00432]\]
                                                                                                                                    Promotes re-epithelialization                                                                               

  Urinary incontinence                              Polyacrylamide hydrogel                                                         Facilitates urinary incontinence symptoms for patients that are ineligible for midurethral sling surgery\   \[[@B229-pharmaceutics-11-00432]\]
                                                                                                                                    Low rate of adverse effects                                                                                 

  Cerebrospinal fluid leak                          Fibrin sealant                                                                  Efficient adjunct to dural sutures repair\                                                                  \[[@B230-pharmaceutics-11-00432]\]
                                                                                                                                    Safe profile                                                                                                

  Diabetes, foot ulcer                              Hydrogel/hydrocolloid                                                           Promotes wound healing\                                                                                     \[[@B231-pharmaceutics-11-00432]\]
                                                                                                                                    Confers protection\                                                                                         
                                                                                                                                    Stimulates epithelial migration                                                                             

  Intracranial aneurysm                             Hydrogel coils                                                                  Efficient endovascular coil embolization\                                                                   \[[@B232-pharmaceutics-11-00432]\]
                                                                                                                                    Safe profile                                                                                                

  Cerebral aneurysm                                 Improves aneurysm packing\                                                      \[[@B233-pharmaceutics-11-00432]\]                                                                          
                                                    Decreases major recurrence                                                                                                                                                                  

  Submucosal tumor of gastrointestinal tract        Calcium-alginate gel                                                            No adverse events and no tissue injuries\                                                                   \[[@B234-pharmaceutics-11-00432]\]
                                                                                                                                    Increases mucosa-elevating capacity                                                                         

  Oral mucositis                                    Mucoadhesive hydrogel                                                           Safety profile and tolerability\                                                                            \[[@B235-pharmaceutics-11-00432]\]
                                                                                                                                    Reduces oral mucositis symptoms                                                                             

  Myoma                                             Resorbable hydrogel                                                             Safety and efficacy\                                                                                        \[[@B236-pharmaceutics-11-00432]\]
                                                                                                                                    Reduces post-operative adhesions formation following myomectomy                                             

  Pulmonary emphysema                               Fibrin hydrogel                                                                 Safe profile and no major adverse effects\                                                                  \[[@B237-pharmaceutics-11-00432],[@B238-pharmaceutics-11-00432]\]
                                                                                                                                    Promotes the formation of scar tissue\                                                                      
                                                                                                                                    Improves lung function                                                                                      

  Lung cancer biopsy                                Hydrogel plug                                                                   Reduces postbiopsy pneumothorax and other complications associated with CT guided coaxial needle biopsy     \[[@B239-pharmaceutics-11-00432]\]

  Ischemic cardiomyopathy                           Gelatin hydrogel                                                                Controlled release of fibroblast growth factor\                                                             \[[@B240-pharmaceutics-11-00432]\]
                                                                                                                                    Increases the formation of cardiovascular networks\                                                         
                                                                                                                                    Improves ventricular function                                                                               

  Heart failure                                     Alginate hydrogel                                                               Efficiency and safety profile\                                                                              \[[@B241-pharmaceutics-11-00432],[@B242-pharmaceutics-11-00432]\]
                                                                                                                                    No serious adverse effects\                                                                                 
                                                                                                                                    Increases exercise capacity                                                                                 

  Elective cranial procedures with dural incision   PEG hydrogel                                                                    Safe profile\                                                                                               \[[@B243-pharmaceutics-11-00432]\]
                                                                                                                                    Dural closure augmentation\                                                                                 
                                                                                                                                    Rapid preparation and application                                                                           

  Neuropathic pain                                  Lidocaine plaster                                                               Safety and tolerability profile\                                                                            \[[@B244-pharmaceutics-11-00432]\]
                                                                                                                                    Relevant pain reduction                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
